ENTRY       D00633                      Drug
NAME        Dopamine hydrochloride (JP18/USP);
            Actopamin (TN);
            Intropin (TN)
PRODUCT     DOPAMINE HCI (HF Acquisition Co LLC)
            DOPAMINE HCI (HF Acquisition Co. LLC)
            DOPAMINE HCI IN 5% DEXTROSE (HF Acquisition Co LLC)
            DOPAMINE HYDROCHLORIDE (HF Acquisition Co LLC)
            DOPAMINE HYDROCHLORIDE (Henry Schein)
            DOPAMINE HYDROCHLORIDE (Henry Schein)
            DOPAMINE HYDROCHLORIDE (Hospira)
            DOPAMINE HYDROCHLORIDE (Medical Purchasing Solutions)
            DOPAMINE HYDROCHLORIDE AND DEXTROSE (Baxter Healthcare Corporation)
            DOPAMINE HYDROCHLORIDE IN DEXTROSE (Hospira)
  GENERIC   DOPAMINE HYDROCHLORIDE (HF Acquisition Co LLC)
            DOPAMINE HYDROCHLORIDE (HF Acquisition Co LLC)
            DOPAMINE HYDROCHLORIDE (Hikma Pharmaceuticals USA)
FORMULA     C8H11NO2. HCl
EXACT_MASS  189.0557
MOL_WEIGHT  189.6394
CLASS       Cardiovascular agent
             DG01703  Cardiotonic
              DG01699  Catecholamine cardiotonic
            Neuropsychiatric agent
             DG01472  Dopamine agonist
            Metabolizing enzyme substrate
             DG01592  COMT substrate
             DG02917  MAO substrate
              DG03179  MAOB substrate
            Transporter substrate
             DG02854  SLC22A2 substrate
REMARK      Therapeutic category: 2119
            ATC code: C01CA04
            Chemical structure group: DG00213
            Product (DG00213): D00633<JP/US>
EFFICACY    Cardiotonic, Dopamine receptor agonist
  DISEASE   Myocardial infarction [DS:H01730]
COMMENT     Catecholamine derivative
TARGET      DRD [HSA:1812 1813 1814 1815 1816] [KO:K04144 K04145 K04146 K04147 K05840]
  PATHWAY   hsa04020(1812+1816)  Calcium signaling pathway
            hsa04080(1812+1813+1814+1815+1816)  Neuroactive ligand-receptor interaction
            hsa04728(1812+1813+1814+1815+1816)  Dopaminergic synapse
METABOLISM  Enzyme: MAOB [HSA:4129], COMT [HSA:1312]
            Transporter: SLC22A2 [HSA:6582]
INTERACTION  
STR_MAP     map07213  Dopamine receptor agonists/antagonists
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             C CARDIOVASCULAR SYSTEM
              C01 CARDIAC THERAPY
               C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
                C01CA Adrenergic and dopaminergic agents
                 C01CA04 Dopamine
                  D00633  Dopamine hydrochloride (JP18/USP) &lt;JP/US&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               211  Cardiotonics
                2119  Others
                 D00633  Dopamine hydrochloride (JP18/USP)
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01703  Cardiotonic
               DG01699  Catecholamine cardiotonic
                DG00213  Dopamine
                 D00633  Dopamine hydrochloride
             Neuropsychiatric agent
              DG01472  Dopamine agonist
               DG00213  Dopamine
                D00633  Dopamine hydrochloride
             Metabolizing enzyme substrate
              DG01592  COMT substrate
               DG00213  Dopamine
                D00633  Dopamine hydrochloride
              DG02917  MAO substrate
               DG03179  MAOB substrate
                DG00213  Dopamine
                 D00633  Dopamine hydrochloride
             Transporter substrate
              DG02854  SLC22A2 substrate
               DG00213  Dopamine
                D00633  Dopamine hydrochloride
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Dopamine
                DRD
                 D00633  Dopamine hydrochloride (JP18/USP) &lt;JP/US&gt;
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D00633  Dopamine hydrochloride
              D00633  Dopamine hydrochloride injection
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00633
             Drug transporters
              D00633
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01703  Cardiotonic
               DG01699  Catecholamine cardiotonic
                DG00213  Dopamine
             Neuropsychiatric agent
              DG01472  Dopamine agonist
               DG00213  Dopamine
             Metabolizing enzyme substrate
              DG01592  COMT substrate
               DG00213  Dopamine
              DG02917  MAO substrate
               DG03179  MAOB substrate
                DG00213  Dopamine
             Transporter substrate
              DG02854  SLC22A2 substrate
               DG00213  Dopamine
DBLINKS     CAS: 62-31-7
            PubChem: 7847699
            ChEBI: 4698
            LigandBox: D00633
            NIKKAJI: J237.158H
ATOM        12
            1   C8y C    28.7000  -14.7000
            2   C8x C    27.5100  -14.0000
            3   C8x C    28.7000  -16.1000
            4   C1b C    29.8900  -14.0000
            5   C8y C    26.3200  -14.7000
            6   C8x C    27.5100  -16.8000
            7   C1b C    31.1500  -14.7000
            8   C8y C    26.3200  -16.1000
            9   O1a O    25.0600  -14.0000
            10  N1a N    32.3400  -14.0000
            11  O1a O    25.0600  -16.8000
            12  X   Cl   32.5500  -16.8000
BOND        11
            1     1   2 1
            2     1   3 2
            3     1   4 1
            4     2   5 2
            5     3   6 1
            6     4   7 1
            7     5   8 1
            8     5   9 1
            9     7  10 1
            10    8  11 1
            11    6   8 2
///
